TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery
Brief Summary: The SYNTAX trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: abciximab followed by implantation of bare metal stent | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: abciximab and Sirolimus eluting stent | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: tirofiban and bare metal stent | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Other: tirofiban and sirolimus-eluting stent | Intervention Type: OTHER; Name: abciximab followed by implantation of bare metal stent; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: abciximab and Sirolimus eluting stent; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: tirofiban and bare metal stent; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: tirofiban and sirolimus-eluting stent; Assigned to Arm(s): 4
B: Arm Label: Investigational device; Type: EXPERIMENTAL; Interventions: Device: AMS-3.0 | Intervention Type: DEVICE; Name: AMS-3.0; Assigned to Arm(s): Investigational device
C: Arm Label: PCI with DES; Type: EXPERIMENTAL; Interventions: Device: Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent | Arm Label: CABG (coronary artery bypass graft); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Coronary Artery Bypass Surgery | Intervention Type: DEVICE; Name: Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent; Assigned to Arm(s): PCI with DES | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass Surgery; Assigned to Arm(s): CABG (coronary artery bypass graft)
D: Arm Label: Everolimus Arm; Type: EXPERIMENTAL; Interventions: Drug: Everolimus Eluting Coronary Stent System | Arm Label: non drug eluting stent Arm; Type: ACTIVE_COMPARATOR; Interventions: Device: cobalt chromium balloon expandable stent ( non drug eluting stent Arm) | Intervention Type: DRUG; Name: Everolimus Eluting Coronary Stent System; Assigned to Arm(s): Everolimus Arm | Intervention Type: DEVICE; Name: cobalt chromium balloon expandable stent ( non drug eluting stent Arm); Assigned to Arm(s): non drug eluting stent Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Estrogen in the Prevention of Atherosclerosis Trial
Brief Summary: The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).


Options:
A: Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Hormone replacement therapy; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Estrogen in the Prevention of Atherosclerosis Trial
Brief Summary: The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).


Options:
A: Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Loss - Louisiana Obese Subjects Study
Brief Summary: LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for individuals with extreme obesity (body mass index \[BMI\] 40-60 kg/m2). The intensive medical treatment is designed to produce 25% weight loss from baseline and to maintain at least 20% weight loss from baseline. The intensive medical treatment is compared to a usual care treatment model where individuals utilize self directed approaches to weight loss. The active treatment period is three years, followed by two years of observation.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet weight loss with SlimFast and human counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet weight loss with SlimFast and computer counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet weight loss program with SlimFast; Assigned to Arm(s): N/A
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Face-to-face maintenance program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet maintenance program; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Loss - Louisiana Obese Subjects Study
Brief Summary: LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for individuals with extreme obesity (body mass index \[BMI\] 40-60 kg/m2). The intensive medical treatment is designed to produce 25% weight loss from baseline and to maintain at least 20% weight loss from baseline. The intensive medical treatment is compared to a usual care treatment model where individuals utilize self directed approaches to weight loss. The active treatment period is three years, followed by two years of observation.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care
B: Arm Label: 5As Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 5As Team Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 5As Team Intervention; Assigned to Arm(s): 5As Team Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2
D: Arm Label: Family Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Family Intervention | Arm Label: Motivational Interviewing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral Family Intervention; Assigned to Arm(s): Family Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomised, Double-Blind, Placebo-Controlled Roll Over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Brief Summary: The purpose of this study is to determine the safety of darbepoetin alfa beyond 16 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.


Options:
A: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
C: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W
D: Arm Label: Darbepoetin alfa - Group A; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo- Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa - Group A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo- Group B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomised, Double-Blind, Placebo-Controlled Roll Over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Brief Summary: The purpose of this study is to determine the safety of darbepoetin alfa beyond 16 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.


Options:
A: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): N/A
C: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)
Brief Summary: The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 5
B: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
C: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)
Brief Summary: The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.


Options:
A: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: methotrexate, Drug: Placebo, triple | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: Sulfasalazine, Drug: Hydroxychloroquine, Drug: Placebo, etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Sulfasalazine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo, triple; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo, etanercept; Assigned to Arm(s): Arm 2
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)
Brief Summary: The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: Infliximab 5 mg/kg; Type: N/A; Interventions: Drug: Infliximab 5 mg/kg | Arm Label: Infliximab 10 mg/kg; Type: N/A; Interventions: Drug: Infliximab 10 mg/kg | Arm Label: Placebo; Type: N/A; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Infliximab 5 mg/kg; Assigned to Arm(s): Infliximab 5 mg/kg | Intervention Type: DRUG; Name: Infliximab 10 mg/kg; Assigned to Arm(s): Infliximab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Rituximab Intravenous Infusion; Type: EXPERIMENTAL; Interventions: Drug: Anti-CD20 (rituximab) | Arm Label: Placebo Intravenous Infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Anti-CD20 (rituximab); Assigned to Arm(s): Rituximab Intravenous Infusion | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo Intravenous Infusion
D: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)
Brief Summary: The purpose of this study objective will be to evaluate the efficacy and safety of etanercept 50 mg BIW in RA subjects who showed a sub-optimal response to standard dose etanercept (50 mg QW) and concomitant methotrexate therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 3
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: MTX | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Infliximab, Drug: MTX | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: D